metyrapone has been researched along with Hypertrophy, Left Ventricular in 1 studies
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medical therapy can be used to treat Cushing syndrome and can result in improvement in the cardiovascular pathology." | 1.72 | Cushing syndrome as a failed cardiac screen in a patient with McCune-Albright syndrome: a case report. ( Al Zubeidi, H; Diaz-Thomas, A; Foster, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foster, C | 1 |
| Al Zubeidi, H | 1 |
| Diaz-Thomas, A | 1 |
1 other study available for metyrapone and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Cushing syndrome as a failed cardiac screen in a patient with McCune-Albright syndrome: a case report.
Topics: Cushing Syndrome; Dexamethasone; Fibrous Dysplasia, Polyostotic; GTP-Binding Protein alpha Subunits; | 2022 |